PostEra uses our Protonplatform to develop medicines for diseases. We do this in two ways:
- 1. An internal pipeline focussed on Women’s Health and Fertility
- 2. A co-discovery pipeline with pharma partners across a wide variety of therapeutics areas
The PostEra Pipeline
| Owner | Disease | Target | Molecule | Early Discovery | Late Discovery | IND-Enabling | Clinic | PostEra Rights | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | AKR1C3 | PERA-5720 | Wholly Owned | ||||||||
| Male Infertility | LHCGR | PERA-8103 | Wholly Owned | |||||||
| Female Infertility | FSHR | Wholly Owned | ||||||||
Partnered Pipeline | |||||||||||
  | 4 preclinical programs across | Milestones | |||||||||
 | |||||||||||
CO-DISCOVERY
We partner with organizations to develop small molecule drug candidates.
Here’s how we typically work
01
Biopharma partner selects biological targets and helps define the assay cascade and Target-Product-Profile.
02
PostEra drives the discovery of safe and effective small molecules against those targets until the nomination of Development Candidate(s).
03
The Partner and PostEra agree on who shall sponsor the asset into IND-enabling studies and the Clinic.
